- Benitec Biopharma Inc (NASDAQ: BNTC) reports an interim analysis of the BB-301 Pilot Dosing study conducted in large animal subjects.
- BB-301 a genetic medicine directly injected into the pharyngeal muscles. It employs the proprietary platform, which allows for a "Silence and Replace" approach to the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).
- OPMD is caused by a mutation in the gene encoding poly(A) binding protein nuclear 1 (PABPN1), wherein patients lose the ability to swallow liquids and solids.
- The interim analysis showed biologically significant, highly-consistent, dose-dependent levels of BB-301 tissue transduction, with BB-301 copy numbers ranging from 1.7 copies per cell up to 8.6 copies per cell achieved after a single administration of increasing doses of BB-301.
- Durable and biologically significant levels of target gene knockdown (inhibition of the expression of the gene encoding PABPN1) were observed.
- Low-dose, intermediate-dose, and high-dose BB-301 administration achieved similar inhibition levels, with an average of 74% inhibition of PABPN1 expression observed across all doses.
- Following an optimized route and method of administration, Benitec demonstrated a 248-fold improvement and a 111-fold improvement in BB-301 transduction of the two key pharyngeal muscles relative to the levels of BB-301 transduction observed in the analogous Beagle dog study conducted by the previous BB-301 licensee.
- The company has scheduled a Scientific Advice Meeting in France in May to review the interim data and the Phase 1 clinical trial design.
- The company will provide additional pipeline updates in 2H2021. Plans to initiate human trials of BB-301 in OPMD patients in 2022.
- Price Action: BNTC gained 5.8% at $3.97 in premarket trading on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
